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outpatients with CAO regularly using home aerosol therapy and referring to chest clinics. The
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were using home nebulisers but also experienced with inhalers vs. those only using inhalers and
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Risk of inhaler mishandling and long-term nebulizer use 669Information was gained evaluating the responses to a standardised questionnaire on home
aerosol therapy and the observations of inhaler technique.
Weenrolled1527patients (58%males;mean SE; aged61.1 0.4 years; FEV1%pred69.9 0.6;
51% and 44% respectively suffering from COPD and asthma) who were only inhaler users (OIU
group) and137 (85%males; aged 67.7 1.3 years; FEV1%pred 62.3 2.9; 60%and23% respectively
suffering from COPD and asthma) who were using both nebulisers and inhalers (NIU group).
Nebuliser users were older, had more severe obstruction, related symptoms and health care
resources utilisation. Nebulisers users performed more critical inhalers errors than those of the
OIU group (49% vs. 36%; pZ 0.009).
We conclude that our patients with CAO and regular nebuliser treatment had advanced age,
severe respiratory conditions and common inhaler misuse.
ª 2011 Elsevier Ltd. All rights reserved.Introduction
Aerosolised drugs are the mainstay of asthma and chronic
obstructive pulmonary disease (COPD) pharmacological
management. The production of therapeutic aerosols
requires specific delivery devices, such as hand-held
inhalers and nebulisers. The most currently used guide-
lines for asthma1,2 and COPD3,4 management, as well as for
nebuliser5e7 and aerosol therapy8 do not provide sufficient,
specific guidance on the selection of the most appropriate
device. Consequently, and accordingly to the local habits,
large variability exists among countries about the diffusion
of different delivery devices for aerosol therapy.9,10
Nebulisers are cumbersome, time-consuming and less
convenient than inhalers.5 However, many adult patients,
mainly elderly, use nebulisers at home not only for occa-
sional episodes of acute severe bronchospasm but even for
regular long-term utilisation.11e14 We have previously
investigated the device preference in a group of 636 Italian
patients with chronic lung diseases who were regularly
using nebulisers at home, but were also experienced with
inhalers: half of these subjects felt that nebulisers were
more effective than inhalers and preferred them.13 A
systematic review does not confirm that nebulisers are
more effective than inhalers; when appropriate doses of
drugs are compared and devices are optimally used, inhaler
and nebulisers are clinically equivalent.8 So, the perception
of greater benefit of nebulisers over inhalers has been
previously attributed to undemonstrated adjunctive prop-
erties, such as the capability of reducing the thickness of
sputum, or a placebo effect of the mist, perhaps associated
to the common use of nebulisers in emergency room
departments15 and hospital.16 We hypothesized that
another possibility explaining because some patients
consider nebulisers as the most effective delivery device
for aerosol therapy is the poor inhaler technique. Critical
inhaler mishandlings may be responsible of inconsistent
lung drug delivery. To our knowledge, no previous study did
investigate this hypothesis, even if it is known that a proper
inhaler use is a challenge for many subjects.17
The GENEBI Project (ClinicalTrials.gov identifier:
NCT0925-0586) is a study performed in 2008 by the AIPO
(Associazione Italiana Pneumologi Ospedalieri) Educational
Group for evaluating home aerosol practice in a large
sample of experienced patients with chronic airflowobstruction (CAO) referring to chest clinics. Data obtained
from this survey have shown that mishandling remains
common in real life even with the newer more user-friendly
inhalers.18 Most of the enrolled patients were Only Inhaler
Users (OIU group), but a subset was also using nebulisers
(Nebuliser and Inhaler Users Z NIU group).
The primary outcomes of the present study were to
investigate 1) whether subjects of the NIU group per-
formed more critical inhaler errors than those of the OIU
group; 2) the characteristics of subjects of the NIU group
in comparison with the OIU population. The secondary
outcome was to analyse current nebuliser practice in
Italy.
Materials and methods
The GENEBI Project was a cross-sectional, observational
study carried out in 24 chest clinics throughout Italy to
evaluate home aerosol practice. These centers were
located at different latitudes across Italy and included
highly urbanized as well as rural areas, thus encompassing
a wide range of geographical and environmental settings.
The study was performed from July to September 2008. The
study was conducted in accordance with the declaration of
Helsinki. The study protocol was approved by the ethics
committee of the participating centers.
Study population
During the study period all adult (age greater than 18 years)
outpatients with spirometrically confirmed Chronic Airflow
Obstruction (CAO), attending one of the centers for
a scheduled visit and practicing aerosol therapy regularly at
home were considered eligible for participation. To the aim
of the present survey, regular use was defined as
prescription of aerosol therapy at least once daily for 4
weeks in the 3 months before the enrollment and self-
reports of effective utilisation. To meet the busy clinical
practice of chest clinics with limited time, but to minimize
selection bias, investigators were required to enroll their
first two consecutive eligible patients in each working day.
The enrollment always occurred after full explanation of
the study and written informed consent; no one refused to
participate to the survey.
670 A.S. Melani et al.Method
We have already described the study method in detail.18
Briefly, home aerosol practice was evaluated using
a standardised questionnaire, which included a self- and an
investigator-compiled part, prepared by the AIPO Educa-
tional Group members. Each self-filled part had queries
about home aerosol practice with source and modalities of
education received. It also included 26 items, mostly
(N Z 23) of closed type, about nebuliser equipment, use,
maintenance and subject’s opinion and preference for
different delivery devices. The physician-filled part evalu-
ated primary respiratory diagnosis, the prescribed devices
and the drugs used. On enrollment, subjects underwent
a spirometry performed according to the accepted guide-
lines. Then each patient demonstrated the inhalation
technique with all used devices to the investigator in
a quiet area using a placebo device. Patients were asked to
use their aerosol just as if they would be at home. For each
center, a single trained investigator evaluated the modali-
ties of inhaler use; to standardize their findings, periodic
meetings were held with all the participating observers.
Investigators were blinded to the results of the self-
administered questionnaire when recording the mode of
inhalation. All observations of inhaler use were reported in
accordance to a standardised device checklist, previously
described, obtained from review of literature and discussed
in detail.18 This checklist included a variable number of
steps for each inhaler focusing the analysis on critical errors
(see their list in Tables 2 and 3), which are likely to make
therapy aerosol useless.
Statistical analysis
Statistical analysis was performed using generalized linear
models (Stata 9, www.stata.com) with Gaussian orTable 1 Some demographic and clinical characteristics of subje
both nebulisers and inhalers (NIU group).
Characteristic NIU grou
Gender, %
 Males 85
 Females 15
Main respiratory diagnosis, %
 COPD 51
 Asthma 44
 Others 5
Smoking status, %
 Smokers 16
 Ex-smokers 59
 Never smokers 25
Educational level, %
 Fifth grade or less 55
 Sixth to eighth grade 25
 High school 11
 University 8
Subjects with resting oxyhaemoglobin saturation
<90% whilst breathing air, % 22binomial/logit family, as appropriate, including the center
as a cluster (which corresponds to add it as a random effect
variable) to obtain a robust standard error. Data are pre-
sented as the mean  SE unless otherwise specified. A p-
value of <0.05 for a two-tailed test was considered as
significant.Results
The GENEBI Project included 1527 subjects with CAO who
were only inhaler users (OIU group) and 196 who were
regularly using nebulisers. Of the latters, 22, 18 and 19
subjects, respectively, had used inhalers in the past, were
using them occasionally, or never; the remaining 137
subjects (the NIU group) were utilizing one or more
inhalers regularly. Our data about nebuliser users only
came out from 14 of the 24 centers participating to the
present study; data about nebuliser users who were also
utilising inhalers came out from 12 of the 24 centers
participating to the present study. The demographic and
the clinical characteristics among groups of nebuliser users
did not differ (data not shown). The subjects of the NIU
group were older (mean age  SE of 67.7  1.3 vs.
61.1  0.4; p < 0.0001) and with more severe obstruction
(mean FEV1% pred  SE of 62.3  2.9 vs. 69.9  0.6;
p < 0.0001; mean FEV1/VC  SE of 61.0  1.2 vs.
66.3  0.4; p < 0.0001) than those of the OIU group. Other
demographic and clinical characteristics of the OIU and
NIU groups are described in Table 1: the NIU group also had
a greater percentage of males, subjects with COPD,
related symptoms (breathlessness episodes, sleep distur-
bances, limitations in everyday life, feeling of inadequate
respiratory disease control) in the last month prior to the
study and unscheduled health care resources (hospital-
isations, emergency room visits and antibiotic courses)
utilisation in the last year prior to enrollment (p < 0.001cts who were only using inhalers (OIU group) and those using
p, n Z 137 OIU group, n Z 1527 Difference
58 P < 0.0001
42
60 P < 0.0001
23
17
15 NS
52
33
42 P < 0.0001
23
27
8
7.5 P < 0.0001
Table 1 (continued )
Characteristic NIU group, n Z 137 OIU group, n Z 1527 Difference
Subjects reporting sputum >3 months per year
in the 2 last years, %
72 41 P < 0.0001
Diskus users, % 30 28 NS
HandiHaler users, % 36 31 NS
Aerolizer users, % 5 5 NS
MDIs users, % 50 50 NS
Turbohaler users, % 21 22 NS
Hospitalisations in the last year, %
 Never 38 72 P < 0.0001
 One 33 18
 More than one 29 10
Antibiotic courses in the last year, %
 Never 15 34 P < 0.0001
 One 20 31
 More than one 65 35
Emergency room visits in the last year, %
 Never 40 76 P < 0.0001
 One 32 16
 More than one 28 8
Limited doing desired everyday life due to respiratory
symptoms in the last month, %
 Always or most of time 50 25 P < 0.0001
 Sometimes 31 27
 Seldom or never 19 48
Breathlessness episodes in the last month, %
 More times a day 25 17 P < 0.0005
 At least once a day 13 13
 A few times a week 24 15
 Seldom or never 38 55
Sleep disturbances due to respiratory symptoms
in the last month, %
 Always 6 5 P < 0.001
 Often 21 16
 Sometimes (once a week) 31 22
 Seldom or never 42 57
Rate respiratory disease control in the last month, %
 Not at all 12 4 P < 0.001
 Poorly controlled 17 14
 Somewhat controlled 27 22
 Well or fully controlled 44 59
Risk of inhaler mishandling and long-term nebulizer use 671for all these variables). After adjustment for age, the
difference in gender and primary respiratory diagnosis lost
significance, but the NIU group continued to show greater
airflow obstruction (FEV1/VC%: p Z 0.036), more symp-
toms and health care resources utilisation (p < 0.05 for all
these variables).
We have a total of 2288 records of inhaler technique
(data of 31 subjects were lacking). The subjects of the NIU
and OIU group performed, respectively, 154 and 2134 of
these observations. The results are shown in Tables 2 and 3.
Critical mistakes were distributed among users of all the
inhalers for both groups. Overall, the subjects of the NIU
group performed at least a critical inhaler error more often
than those of the OIU group (49% vs. 36%; p Z 0.009). The
percentage of subjects of the OIU group reporting some
instruction by health caregivers at first inhaler prescriptionwas greater than that of the NIU group (85% vs. 65%;
p < 0.001); similarly, as compared to the NIU population,
a greater percentage of subjects of the OIU group had
received a physical demonstration of inhaler use at first
prescription (59% vs. 43%; p Z 0.006) and at least a prac-
tical check of inhaler technique at follow-up visits (50% vs.
38%; p Z 0.01). Even after adjustment for age, device and
any type of instruction by health caregivers, the frequency
of critical inhaler errors for the NIU group remained
significantly greater than for the OIU group (pZ 0.03). The
percentage of subjects of the NIU group with at least
a critical inhaler error who, respectively, considered neb-
ulisers more effective than inhalers (56% vs. 20%; OR
3,8  1.1; p < 0.001) and preferred the first device (48% vs.
24%; OR 3.4  1.3; p Z 0.001) was greater than for those
without any critical inhaler error.
Table 2 Errors of inhaler technique with MDIs for the group of subjects using only inhalers (OIU group) and that using both
inhalers and nebulisers (NIU group).
Checklist of inhalation technique errors NIU group OIU group P-value
Failure to remove cap,a% 0 0 NS
Not shaking the inhaler, % 45 36 NS
Hold the mouthpiece inhaler between open lips, % 35 18 P < 0.001
Not holding the inhaler in the upright position, % 12 9 NS
No full exhalation before actuation, % 56 50 NS
More actuations for a single inhalation, % 22 18 NS
Actuation against teeth, lips, or tongue,a % 1 0 NS
Actuation in the second half of inspiration, % 24 21 NS
Activation after end or before start of inhalation,a % 9 5 NS
Stopping inhalation immediately after firing,a % 14 10 NS
Forceful inhalation,a % 68 50 P Z 0.002
Inhalation through nose whilst and after actuation,a % 6 3 NS
No or short (less than 2e3 s) breath-holding after inhalation,a % 49 48 NS
Data are presented as the percentage of subjects for the group performing the error compared to the total number of observations. MDI,
Metered Dose Inhaler, NS, non-statistical difference.
a Critical mistakes.
672 A.S. Melani et al.Some details of nebuliser practice are displayed in Table
4. Many patients reported that they chose the nebuliser
equipment themselves. Most patients (94%) chose the
interface system themselves, without any medical infor-
mation. A minority of subjects had received some informa-
tion about nebuliser use and maintenance by health
caregivers. Most patients (78%) also reported that they did
never receive any instruction on the optimal fill volume or
drug solvent; the mean fill volume was 3.8 ml. Fifty patients
reported information useful to gain, at least partially, the
used nebuliser brand; eighteen different models were re-
ported at all with prevalence for the Nebula (NZ 7) and the
Bimboneb (N Z 11) (Markos-Mefar, Bovezzo, BS), the Vent-
Stream (NZ 4) and the SideStream (NZ 5), mainly (NZ 7)
powered by an Artsana compressor (Artsana, Grandate, CO),
the Clenny (N Z 5) (Medel, S.Polo di Torrile, PR) and the
ultrasonic Universal II (N Z 3) (FLAEM, S.Martino della Bat-
taglia, BS). According to the available information, jet
nebulisers largely prevailed (94% of total) over ultrasonic
ones. A minority of jet nebuliser users (16% of total) were
using a glass reservoir. The most commonly used types of
drugs were corticosteroids (N Z 104), bronchodilators
(N Z 93), mucolytics (N Z 16) and cromons (N Z 19). In
decreasing order, the most widely used drugs were beclo-
methasone dipropionate (NZ 67, at a daily dosage ranging
from 0.4 to 1.6 mg), salbutamol (NZ 79, up to a daily dosage
of 3.75 mg), ipratropium bromide (N Z 59, up to a daily
dosage of 1.25 mg), flunisolide (NZ 21, at a daily dosage of
1e3 mg), nedocromil (N Z 19), fluticasone propionate
(N Z 11, at a daily dosage of 1e2 mg), fenoterol (N Z 7),
oxitropium (NZ 5) and budesonide (NZ 5, at a daily dosage
of 0.5e1.5 mg). Most patients (95%) mixed more active drugs
for each nebulisation; more than two third of mixtures
included bronchodilators with corticosteroids.Discussion
We have found that, as compared to the OIU group, the
subjects with CAO using nebulisers were older, with moreunscheduled health care resources utilisation, severe
obstruction and respiratory symptoms. The finding that the
most severely ill population with CAO often uses home neb-
ulisers is not new.19,20 More interestingly,wehavealso shown
that subjects of the NIU group performed more critical
inhaler errors than those of theOIU group. To our knowledge,
no previous study did report that subjects using nebulisers
were particularly prone to inhaler misuse. Possibly, poor
inhaler techniquemay explain because many nebuliser users
perceived nebulisers as more effective than inhalers and
prefer them despite they are less convenient. Of course, our
study has some limitations. Firstly, our choice of critical
inhaler errors for each device is arbitrary, although based on
previous literature.18 Secondly, our observations of inhala-
tion technique rely on investigators’ judgments and have
subjective basis. However, we think that our findings are
consistent and generalizable, as they include a very large
sample of subjects, the used method was standardized and,
overall, our findings were in accordance with the results of
reviews including studies with similar design.21,22 Unex-
pectedly, we have also shown that subjects of the NIU group,
often older and severely ill, received less instruction on
inhaler technique than those of theOIU group. It is difficult to
find a logical explanation to this observation. This finding is
certainly a bias of the prescribing physicians: they, perhaps,
estimating good inhaler use as a difficult challenge for this
subset of patients, gave minimal instruction when inhalers
were released for saving time and added the prescription of
nebulisers. However, even after adjustment for any type of
inhaler education, the frequency to inhalermisuse remained
very common in nebuliser users. Possibly, this group of
subjects would require more and more education for
improving inhaler technique. Future studies should investi-
gate if and how proper instruction by health care givers can
revert inhaler mishandling in the short and long-term period
for any range of age, disease and technical skillful, the
amount of education time required for assuring good inhaler
technique with different inhalers and the value of alterna-
tive education methods, such as video, web and booklets;
because a correct inhaler technique may be lost over time,
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Risk of inhaler mishandling and long-term nebulizer use 673other studies should clear if all or only some inhalers required
repeated checks at follow-up visits for maintaining good
inhaler use and the type and the amount of this instruction.
Alternatively, if a subset of older and severely ill patients
requiring aerosol therapy is not able to use available inhalers
correctly despite proper education or unavoidably loses this
skill over time, future studies should clear the characteris-
tics of subjects predicting the need of nebulisers.
Nevertheless, although nebuliser use requires less
cooperation than inhalers, education by health caregivers is
also needed for purchasing a proper nebuliser equipment as
well as for its good set-up and maintenance. Even if this
study was not devised to investigate the nebuliser equip-
ment of our subjects, we think that some results need
a short discussion. We were surprised knowing that
approximately half of our patients reported a length of
more than 30 min for each single nebulisation. The British
Thoracic Society6 guidelines recommend a nebulisation
time for single session not greater than 10 min. Although
the long nebulisation time is only a rough index of equip-
ment performances and may also be due to the commonly
observed practice of mixing more drugs with high fill
volume, we are afraid of suboptimal choices for nebuliser
equipment. Some other findings about nebuliser equipment
are certainly suboptimal: glass reservoirs, which are no
more recommended, remained commonly used as well as
ultrasonic nebuliser, which are not suitable to nebulise
corticosteroids.7 Deficiencies in nebuliser equipment would
be not unexpected, as most of our subjects bought it
themselves. Again, 89% of respondents did never receive
any information by health caregivers and/or retailers on
the correct usage and hygiene of their nebuliser. This
percentage is even worse than that observed in another
nationwide survey (although different in material and
method) on nebuliser practice in Italy carried out on 1999,
where the prescribing physicians specified the operating
conditions of nebulisers to be used and the maintenance,
respectively, in 37% and 24% of cases.11,13 In Italy the
National Health Service usually supplies most nebulised
drugs freely or with a little fee, but most adult subjects
who had received the prescription of nebuliser therapy buy
the device directly. To the authors’ knowledge, except for
local and limited situations, no formal widespread servicing
and monitoring managed by health caregivers is available
for Italian adults. Thus, our subjects using nebulisers not
only were prone to inhaler misuse, but their habits also
seem to be consistent with suboptimal nebuliser practice.
Our data seem to show that the diffusion of home neb-
ulisers varied largely among participating centers.
However, large variations of home nebuliser use are known
according to the different local habits.9,10 Some studies
from the UK and Scandinavian countries have shown that
long-term treatments with home nebulised bronchodilators
may be safe and effective.23e25 Short-acting beta-agonists
and anticholinergics are used throughout Europe, but more
common in Belgium, Germany, Swiss, Norway, Italy and
Portugal.10 However, the practice of home nebuliser
therapy in Italy has some peculiarities, as not only bron-
chodilators, but even mucolytics and corticosteroids are
largely used.10 The use of nebulised mucolytics, even in the
presence of bronchiectasis with thick sputum, is not
evidence-based.26 The large use of nebulised
Table 4 Some characteristics of nebuliser practice in the
studied population.
Item Response, N
Who was the first source of nebuliser therapy
prescription? N Z 133
 General practitioner 59
 Chest physician 71
 Other physician 3
How many times a day do you usually use your
nebuliser? N Z 134
 Once a day 22
 Twice a day 22
 Thrice a day or more 45
 Only on a needed basis 11
How long does your nebulisation last? N Z 104
 Less than 15 min 0
 15e30 min 6
 More than 30 min 50
 After a fixed time 3
 When the liquid drugs finish 42
Did someone give some indication about the type
of nebuliser to buy, N Z 132
 Nurse/physiotherapist 2
 Physician 45
 Retailer 35
 Friend/relative 5
 No-one 13
Did someone ever give some instruction about proper
nebuliser use, N Z 97
 Nurse/physiotherapist/physician 0
 Retailer 11
 Friend/relative 28
 No-one, I have read the package
instruction
61
Did someone ever give some instruction about proper
nebuliser hygiene, N Z 70
 Nurse/physiotherapist/physician 0
 Retailer 11
 Friend/relative 32
 No-one, I have read package
instruction
57
When did you get the liquid formulation into the
reservoir? N Z 144
 When it is possible 4
 Immediately before the use 96
Did you add any solvent to the active drug into the
reservoir? N Z 122
 No 44
 Yes, tap water 2
 Yes, distilled water 7
 Yes, physiologic saline 47
Which do interface system use for the nebulisation?,
N Z 124
 Facemask 62
 Mouthpiece 38
Do you inhale aerosol, N Z 133
 By mouth 47
 By nose 9
 By both nose and mouth 44
Table 4 (continued )
Item Response, N
Do you clean your reservoir, N Z 130
 Always after each nebulisation 9
 Once a week 25
 Less than once a week 66
If you don’t reach dryness, do you throw the residual
liquid formulation away? N Z 120
 Yes 84
 I use it again even some hours
after the first interruption
16
Before washing, do you dismantle your reservoir? N Z 118
 It is not possible 12
 Never 26
 Sometimes 35
 Always 27
After washing, do you dry your reservoir? N Z 134
 Never 64
 Always, even if I don’t wash the
reservoir
9
 Always 27
When did you change your reservoir, N Z 128
 Never 44
 When it is broken 32
 According to the manufacturer
indications
24
If you are also using inhalers, which device do you
offer more benefits, N Z 107
 Nebuliser 61
 Inhaler 29
 No difference 1
If you are also using inhalers, which is the most
comfortable device to use?, N Z 110
 Nebuliser 25
 Inhaler 75
 No difference7 10
If you are also using inhalers, which device do you
prefer to use, N Z 109
 Nebuliser 40
 Inhaler 57
 No difference 12
674 A.S. Melani et al.corticosteroids has been critically discussed,27 but it was13
and, as our study confirms, remains widespread in Italy.
Likewise, BDP, the most commonly nebulised corticosteroid
in our population, is clinically effective when properly
nebulised.28 Another commonly observed finding in our
survey which is not evidence-based is the co-admixture of
more nebulised drugs including corticosteroids. Some
in vitro studies did not show unfavorable physico-chemical
interactions when corticosteroids were mixed with salbu-
tamol and ipratropium bromide.29e31 Other in vitro studies
did not observe negative consequences in terms of both
drug output and aerodynamics when BDP and flunisolide
were mixed with salbutamol using both Nebula and Bim-
boneb32; or when budesonide or BDP were mixed to salbu-
tamol and ipratropium bromide using both VentstreamPro
and Sidestream powered with AirClinic.33 Finally, although
the habit of mixing drugs for nebulisation needs further
Risk of inhaler mishandling and long-term nebulizer use 675confirmation to be suggested, a recent study reviewing the
available studies carried out with mixtures of more neb-
ulised drugs including corticosteroids, has shown good
clinical results. However, in vitro information indicates
that some commercially available nebulisers are unsuitable
for nebulising corticosteroids and even the best systems
offer a rather poor and inconsistent fine particle fraction.34
Conclusion
We conclude that in Italy a subset of patients with chronic
airflow obstruction was regularly using home nebulisers.
These patients often have advanced age, severe respiratory
conditions and common inhaler misuse. Nebuliser practice
also seems to be suboptimally performed. If after proper
instruction they can obtain good inhaler technique and be
effectively switched to the use of these devices, it remains
to be demonstrated; alternatively, subjects who did not
obtain a good inhaler technique should receive proper
tuition for assuring the best nebuliser practice. More
education is needed for these patients because they
receive effective aerosol therapy at home.
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